282 related articles for article (PubMed ID: 35257287)
21. Magic pills: new oral drugs to treat chronic lymphocytic leukemia.
Vitale C; Griggio V; Todaro M; Salvetti C; Boccadoro M; Coscia M
Expert Opin Pharmacother; 2017 Mar; 18(4):411-425. PubMed ID: 28234562
[TBL] [Abstract][Full Text] [Related]
22. Promising therapies for the treatment of chronic lymphocytic leukemia.
Morabito F; Recchia AG; Vigna E; De Stefano L; Bossio S; Morabito L; Pellicanò M; Palummo A; Storino F; Caruso N; Gentile M
Expert Opin Investig Drugs; 2015 Jun; 24(6):795-807. PubMed ID: 25728009
[TBL] [Abstract][Full Text] [Related]
23. Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options.
Sharma S; Rai KR
Cancer; 2019 May; 125(9):1432-1440. PubMed ID: 30807655
[TBL] [Abstract][Full Text] [Related]
24. [Chronic lymphocytic leukaemia: current management].
Aurran-Schleinitz T; Arnoulet C; Ivanov V; Coso D; Rey J; Schiano JM; Stoppa AM; Bouabdallah R; Gastaut JA
Rev Med Interne; 2008 May; 29(5):424-35. PubMed ID: 18359538
[TBL] [Abstract][Full Text] [Related]
25. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
26. Health-related quality of life and economic burden of chronic lymphocytic leukemia in the era of novel targeted agents.
Waweru C; Kaur S; Sharma S; Mishra N
Curr Med Res Opin; 2020 Sep; 36(9):1481-1495. PubMed ID: 32634056
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.
Arruga F; Deaglio S
Handb Exp Pharmacol; 2018; 249():203-229. PubMed ID: 28275912
[TBL] [Abstract][Full Text] [Related]
28. The latest developments with anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.
Evers M; Jak M; Leusen JHW
Expert Opin Biol Ther; 2018 Sep; 18(9):973-982. PubMed ID: 30084674
[TBL] [Abstract][Full Text] [Related]
29. Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm.
Scheffold A; Stilgenbauer S
Curr Oncol Rep; 2020 Feb; 22(2):16. PubMed ID: 32025827
[TBL] [Abstract][Full Text] [Related]
30. Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.
Hartmann TN; Pleyer L; Desch P; Egle A; Greil R
Discov Med; 2009 Oct; 8(42):157-64. PubMed ID: 19833065
[TBL] [Abstract][Full Text] [Related]
31. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
Byrd JC; Jones JJ; Woyach JA; Johnson AJ; Flynn JM
J Clin Oncol; 2014 Sep; 32(27):3039-47. PubMed ID: 25049322
[TBL] [Abstract][Full Text] [Related]
32. [Research advance on fludarabine resistance mechanisms in chronic lymphocytic leukemia cells].
Yao L; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):821-4. PubMed ID: 20561458
[TBL] [Abstract][Full Text] [Related]
33. An update on current and prospective immunotherapies for chronic lymphocytic leukemia.
Emole JN; Locke FL; Pinilla-Ibarz J
Immunotherapy; 2015; 7(4):455-66. PubMed ID: 25917633
[TBL] [Abstract][Full Text] [Related]
34. CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCγ1 activation: evidence from mice and humans.
Martinez-Torres AC; Quiney C; Attout T; Boullet H; Herbi L; Vela L; Barbier S; Chateau D; Chapiro E; Nguyen-Khac F; Davi F; Le Garff-Tavernier M; Moumné R; Sarfati M; Karoyan P; Merle-Béral H; Launay P; Susin SA
PLoS Med; 2015 Mar; 12(3):e1001796. PubMed ID: 25734483
[TBL] [Abstract][Full Text] [Related]
35. Signal transduction inhibitors in chronic lymphocytic leukemia.
Ma S; Rosen ST
Curr Opin Oncol; 2011 Nov; 23(6):601-8. PubMed ID: 21892084
[TBL] [Abstract][Full Text] [Related]
36. Improving treatment for patients with chronic lymphocytic leukemia.
Shanafelt TD
Hematology; 2012 Apr; 17 Suppl 1():S133-6. PubMed ID: 22507801
[TBL] [Abstract][Full Text] [Related]
37. Chronic Lymphocytic Leukemia B-Cell Normal Cellular Counterpart: Clues From a Functional Perspective.
Darwiche W; Gubler B; Marolleau JP; Ghamlouch H
Front Immunol; 2018; 9():683. PubMed ID: 29670635
[TBL] [Abstract][Full Text] [Related]
38. Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming.
Martinez Marignac VL; Smith S; Toban N; Bazile M; Aloyz R
Oncotarget; 2013 Dec; 4(12):2550-66. PubMed ID: 24334291
[TBL] [Abstract][Full Text] [Related]
39. Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.
Skånland SS; Mato AR
Blood Adv; 2021 Jan; 5(1):334-343. PubMed ID: 33570649
[TBL] [Abstract][Full Text] [Related]
40. Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.
Mani R; Mao Y; Frissora FW; Chiang CL; Wang J; Zhao Y; Wu Y; Yu B; Yan R; Mo X; Yu L; Flynn J; Jones J; Andritsos L; Baskar S; Rader C; Phelps MA; Chen CS; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
Leukemia; 2015 Feb; 29(2):346-55. PubMed ID: 24947019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
